# ADC Therapeutics SA (ADCT)

- Sector: Healthcare · Industry: Drug Manufacturers Specialty and Generic
- SEC CIK: 0001771910 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001771910))
- Full page: https://inspectstocks.com/stocks/adct
- Data as of: price 2026-09-25; newest filing used 2026-08-13; latest fiscal period ended 2026-06-30

## Grade

**D** on the growth-and-cash rubric, 2 of 5 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Revenue growing overall | failed | $79.6M | $184.4M |
| Revenue growing recently | failed | $79.6M | $81.4M |
| Free cash flow positive | failed | -$102.3M |  |
| Free cash flow growing overall | passed | -$102.3M | -$102.8M |
| Free cash flow growing recently | passed | -$102.3M | -$141.4M |

Business quality (the + / − mark): 2 of 6 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | failed | -121.8% |  |
| Healthy profit margin | failed | -121.8% |  |
| Strong operating margin | failed | -125.1% |  |
| Good return on equity | passed | 52.1% |  |
| Debt under control | passed | -0.02 |  |
| Turns sales into cash | failed | -128.5% |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, as filed.

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $79.6M |
| Net income, trailing twelve months | -$96.9M |
| Free cash flow, trailing twelve months | -$102.3M |
| Net margin | -121.8% |
| Operating margin | -125.1% |
| Return on equity | 52.1% |
| Debt to equity | -0.02 |
| Diluted EPS, trailing twelve months | -$0.66 |
| Share price | $1.27 |
| Market value | $162.1M |
| Price / sales | 2.0x |

## More on this company

- [Overview](https://inspectstocks.com/stocks/adct)
- [Financial statements](https://inspectstocks.com/stocks/adct/financials)
- [Competitors](https://inspectstocks.com/stocks/adct/peers)
- [Earnings](https://inspectstocks.com/stocks/adct/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.